Newest members contribute to n-Lorem’s scientific and investment expertise to support and expedite efforts to charitably provide medicines to treat patients with nano-rare diseases
SAN DIEGO, Calif., December 14, 2021 (Business Wire) — n-Lorem a nonprofit Foundation, discovering and providing experimental antisense oligonucleotides (ASOs) to nano-rare disease patients (1 to 30 patients worldwide) for free for life, today announced the newest additions to its Board of Directors – Jason Wood and Gene Yeo, Ph.D. and M.B.A.
“My colleagues and I at J. Wood Capital Advisors are deeply committed to bringing hope to patients with nano-rare diseases. We believe that n-Lorem has the technology and expertise to make a difference in the lives of these patients, and we were honored to be able to support the n-Lorem Foundation financially,” said Jason Wood, founder and CEO of J. Wood Capital Advisors. “I am even more thrilled to be able to expand my support and join the Board of Directors where I believe my expertise will be a valuable asset to n-Lorem’s unique charitable funding approach to personalized medicine.”
“As a scientist who has focused their career on understanding RNA processing, RNA-targeted therapeutics like ASOs provide an elegant, versatile and highlyspecific model of disease treatment. Creating a non-profit model to bring this powerful technology to patients with nano-rare diseases is an equally elegant approach,” said Dr. Yeo, Professor of Cellular and Molecular Medicine at the University of California San Diego. “The opportunity to contribute to n-Lorem as part of the foundation’s Board of Directors is an incomparable opportunity to experience the power of science as it translates knowledge from the laboratory into hope for patients.”
“I am pleased to welcome Jason and Gene to our team of dedicated directors who are diligently working with n-Lorem to bring personalized antisense medicines to the patients who are at most need and who are underserved by our health care systems,” said Dr. Stanley T. Crooke, Founder, CEO and Chairman, n-Lorem Foundation. “The work we do at n-Lorem is extremely important to me, and I am honored and privileged to serve on the Board of Directors with such an esteemed group of leaders in the scientific, investment, regulatory, and biotechnology communities. Having the support and guidance from leaders in these areas will be instrumental in expanding our mission of bringing personalized medicines to patients in the nano-rare disease community.”
Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these needy patients and families.
- Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Ultra-Rare Disease
- Watch: n-Lorem Foundation: Creating a Better Future for Ultra-Rare, One Patient at a Time
- Watch: n-Lorem Foundation’s 1st year of Progress
About Jason Wood
Mr. Wood joins n-Lorem with a wealth of finance and investment expertise, with more than 25 years of experience helping companies raise capital. In the last eight years, he has acted as a financial advisor on over $55 billion in capital market transactions. Mr. Wood is the founder and CEO of J. Wood Capital Advisors, an advisory firm and registered broker dealer focused on providing capital structure advice and solutions to corporate clients. Previously, Mr. Wood worked for nearly 20 years at J. P. Morgan, where he was Head of Equity-Linked
Capital Markets for the Americas and a member of the Equity Commitments Committee. Mr. Wood graduated from Princeton University cum laude with a B.A. in Economics.
About Gene Yeo
Dr. Yeo holds a Ph.D. in Computational Neuroscience from the Massachusetts Institute of Technology and an M.B.A from the UC San Diego Rady School of Management. Dr. Yeo is a Professor of Cellular and Molecular Medicine at the University of California San Diego and his primary research interest is in the understanding of the importance of RNA processing and the roles that RNA-binding proteins play in development and disease. Dr. Yeo also has extensive experience in the biotechnology industry as a co-founder of several biotechnology companies and has served on multiple scientific advisory boards.
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 100 applications for treatment with more than 40 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
Amy Williford, Ph.D.
Director of Communications